Progenics Pharmaceuticals Announces Presentations at the 2020 American Society of Clinical Oncology Genitourinary Cancers Sym...
06 Febbraio 2020 - 2:30PM
Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company
developing innovative targeted medicines and artificial
intelligence to find, fight and follow cancer, today announced that
three abstracts highlighting PyLTM (18F-DCFPyL), I-131 1095, and
PSMA AI have been selected for oral and poster presentations at the
upcoming American Society of Clinical Oncology Genitourinary
Cancers Symposium Annual Meeting (ASCO GU) , which will be held
from February 13-15, 2020 in San Francisco, CA. Details on the
presentations are included below.
Date & Time: Thursday
February 13, 2020 from 7:45 a.m. to 9:30 a.m. Pacific
TimeSession Title: Localized Prostate Cancer:
Individualizing Diagnosis, Staging, and
TreatmentTitle: A Prospective Phase 2/3
Multi-Center Study of PSMA-targeted 18F-DCFPyL PET/CT Imaging in
Patients with Prostate Cancer (OSPREY): a subanalysis of regional
and distant metastases detection rates at initial staging by
18F-DCFPyL PET/CT.Abstract No.: 9
Date & Time: Thursday
February 13, 2020 from 11:30 a.m. to 1:00 p.m. Pacific
TimePoster Session Title: Poster Session A:
Prostate Cancer and Trials in Progress Poster Session A: Prostate
CancerTitle: A Deep Learning Algorithm to Predict
Co-Existing Metastatic Disease using Intraprostatic [F18] DCFPyL
PSMA Image Alone in Veterans with Prostate Cancer.Abstract
No.: 25Poster Board No.: A13
Date & Time: Thursday
February 13, 2020 from 5:30 p.m. to 6:30 p.m. Pacific
TimePoster Session Title: Poster Session A:
Prostate Cancer and Trials in Progress Poster Session A: Prostate
CancerTitle: A multicenter, randomized, controlled
phase 2 study: Efficacy and safety of PSMA-targeted radioligand
therapy I-131-1095 (1095) plus enzalutamide (enza) in F-DCFPyL PSMA
scan avid, metastatic castration-resistant prostate cancer (mCRPC)
patients post-abiraterone (abi) progression
(ARROW).Abstract No.: TPS260Poster Board
No.: P4
About PROGENICS
Progenics is an oncology company focused on the
development and commercialization of innovative targeted medicines
and artificial intelligence to find, fight and follow cancer,
including: therapeutic agents designed to treat cancer (AZEDRA®,
1095, and PSMA TTC); prostate-specific membrane antigen (“PSMA”)
targeted imaging agents for prostate cancer (PyL™ and 1404); and
imaging analysis technology (aBSI and PSMA AI). Progenics has three
commercial products, AZEDRA, for the treatment of patients with
unresectable, locally advanced or metastatic pheochromocytoma or
paraganglioma (rare neuroendocrine tumors of neural crest origin)
who require systemic anticancer therapy; and oral and subcutaneous
formulations of RELISTOR® (methylnaltrexone bromide) for the
treatment of opioid-induced constipation, which are partnered with
Bausch Health Companies Inc.
This press release contains projections and
other “forward-looking statements” regarding future events.
Statements contained in this communication that refer to Progenics’
estimated or anticipated future results or other non-historical
facts are forward-looking statements that reflect Progenics’
current perspective of existing trends and information as of the
date of this communication and include statements regarding
Progenics’ strategic and operational plans and delivering value for
shareholders. Forward looking statements generally will be
accompanied by words such as “anticipate,” “believe,” “plan,”
“could,” “should,” “estimate,” “expect,” “forecast,” “outlook,”
“guidance,” “intend,” “may,” “might,” “will,” “possible,”
“potential,” “predict,” “project,” or other similar words, phrases
or expressions. Such statements are predictions only and are
subject to risks and uncertainties that could cause actual events
or results to differ materially. These risks and uncertainties
include, among others: risks associated with the proposed merger
transaction with Lantheus Holdings, Inc.; market acceptance for
approved products; the risk that the commercial launch of AZEDRA
may not meet revenue and income expectations; the cost, timing and
unpredictability of results of clinical trials and other
development activities and collaborations; the unpredictability of
the duration and results of regulatory review of New Drug
Applications (NDA) and Investigational NDAs; the inherent
uncertainty of outcomes in the intellectual property disputes such
as the dispute with the University of Heidelberg regarding
PSMA-617; our ability to successfully develop and commercialize
products that incorporate licensed intellectual property; the
effectiveness of the efforts of our partners to market and sell
products on which we collaborate and the royalty revenue generated
thereby; generic and other competition; the possible impairment of,
inability to obtain and costs of obtaining intellectual property
rights; possible product safety or efficacy concerns, general
business, financial, regulatory and accounting matters, litigation
and other risks; and risks related to changes in the composition of
our Board of Directors following the delivery of shareholder
consents in response to the recent consent solicitation conducted
by one of our shareholders. More information concerning Progenics
and such risks and uncertainties is available on its website, and
in its press releases and reports it files with the Securities and
Exchange Commission (the “SEC”), including those risk factors
included in its Annual Report on Form 10-K for the year ended
December 31, 2018, as updated in its subsequent Quarterly Reports
on Form 10-Q. Progenics is providing the information in this press
release as of its date and, except as expressly required by law,
Progenics disclaims any intent or obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or circumstances or otherwise.
Additional information concerning Progenics and
its business may be available in press releases or other public
announcements and public filings made after this press release. For
more information, please visit www.progenics.com. Information on or
accessed through our website or social media sites is not included
in the company’s SEC filings.
(PGNX-F)
Contact: |
Melissa
Downs |
|
Investor Relations |
|
(646) 975-2533 |
|
mdowns@progenics.com |
Grafico Azioni Progenics Pharmaceuticals (NASDAQ:PGNX)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Progenics Pharmaceuticals (NASDAQ:PGNX)
Storico
Da Giu 2023 a Giu 2024